Cover Image
市場調查報告書

全球囊狀纖維化症 (CF) 治療市場分析與預測

Global Cystic Fibrosis Market Research Report - Forecast to 2022

出版商 Market Research Future 商品編碼 512182
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
全球囊狀纖維化症 (CF) 治療市場分析與預測 Global Cystic Fibrosis Market Research Report - Forecast to 2022
出版日期: 2017年11月30日 內容資訊: 英文 60 Pages
簡介

本報告提供全球囊狀纖維化症 (CF) 治療市場相關調查分析,市場動態,收益成果、預測,主要企業簡介,競爭情形,經濟要素等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 市場動態

  • 推動因素
  • 阻礙因素
  • 機會
  • 課題

第4章 市場要素分析

  • 五力分析模型

第5章 囊狀纖維化症 (CF) 治療市場:各治療方法

  • 簡介
  • 藥物治療
  • 設備
  • 其他

第6章 囊狀纖維化症 (CF) 治療市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 中東、非洲

第7章 企業佔有率分析

第8章 企業簡介

  • AbbVie
  • Allergan Plc
  • Chiesi Farmaceutici S.p.A.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences
  • Novartis AG 
  • Pharmaxis Ltd.
  • PTC Therapeutics
  • Vertex Pharmaceuticals Incorporated

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Introduction

The global cystic fibrosis market was valued at $ 3145.7 million in 2015 and expected to reach at $ 8852.2 million by 2022 at a CAGR of 13.5 % during the forecast period. The major factors responsible for the growth of global cystic fibrosis market are; development of new drugs and therapies, financial support from interest organizations in research and development of cystic fibrosis drugs and others. The growth barriers are high cost of the drugs and treatment among others.

The market is majorly categorized on the basis of treatment method types which is further segmented into medication, devices and other treatments and geographic regions. Globally, North America holds the largest market share of global cystic fibrosis market, registering 43.2 % in 2015.

The scope of Global Cystic fibrosis market study includes the market value, market size and a detailed analysis of vendor products and strategies.

Key Players

The leading players of the Global Cystic fibrosis market are AbbVie, Allergan Plc, Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche AG, Gilead Sciences, Novartis AG, Pharmaxis Ltd., PTC Therapeutics, Vertex Pharmaceuticals Incorporated and others.

Study Objectives of Cystic Fibrosis Market Development and Demand Forecast to 2022 Market

Ø To provide insights about factors, influencing and affecting the market growth

Ø To provide historically and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries

Ø To provide historically and forecast revenue of the market segments based on type, and sub-segment for Global Cystic fibrosis market

Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market

Ø To provide economic factors that influence the Global Cystic fibrosis market

Target Audience

  • Cystic fibrosis companies
  • Hospitals & Clinics
  • Raw Material Suppliers
  • Key executive (CEO and COO) and strategy growth manager

Key Findings

  • On the basis of types, medication segment holds largest market share of global cystic fibrosis market, registering 76.4 % of total market in 2015.
  • US holds 66.48 % market share of North America cystic fibrosis Market and is expected to reach $ 2556.7 million by 2022 from $ 903.7million in 2015.

The reports also cover country level analysis:

  • North America
  • US
  • Canada
  • Europe
  • Western Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Republic of Korea
  • Rest of Asia-Pacific
  • Middle East & Africa

Table of Contents

Table of Contents:

1 Introduction

  • 1.1 Definition
  • 1.2 Scope of Study
  • 1.3 Research Objective
  • 1.4 Assumptions & Limitations
    • 1.4.1 Assumptions
    • 1.4.2 Limitations
  • 1.5 Market Structure

2 Research Methodology

  • 2.1 Research Process
  • 2.2 Primary Research
  • 2.3 Secondary Research

3 Market Dynamics

  • 3.1 Drivers
    • 3.1.1 Introduction
    • 3.1.2 Development of New Drugs and Therapies
    • 3.1.3 Financial Support from CFF in Research and Development of CF Drugs.
  • 3.2 Restraints
    • 3.2.1 Introduction
    • 3.2.2 High Cost of the Drugs and Treatment
  • 3.3 Opportunities
  • 3.4 Challenges
    • 3.4.1 Awareness About the Rare Disease in the Developing Countries

4 Market Factor Analysis

  • 4.1 Porter's Five Forces Model
    • 4.1.1 Bargaining Power of Suppliers
    • 4.1.2 Bargaining Power of Buyers
    • 4.1.3 Threat of New Entrants
    • 4.1.4 Threat of Substitutes
    • 4.1.5 Intensity of Rivalry

5 Cystic Fibrosis Market, By Treatment Method

  • 5.1 Introduction
  • 5.2 Medication
  • 5.3 Devices
  • 5.4 Other Treatments

6 Cystic Fibrosis Market, By Regions

  • 6.1 Introduction
  • 6.2 North America
  • 6.3 Europe
  • 6.4 Asia-Pacific
  • 6.5 Middle East & Africa

7 Company Share Analysis

8 Company Profile

  • 8.1 AbbVie
    • 8.1.1 Company Overview
    • 8.1.2 Product Overview
    • 8.1.3 Financials
    • 8.1.4 Key Developments
  • 8.2 Allergan Plc
    • 8.2.1 Company Overview
    • 8.2.2 Product Overview
    • 8.2.3 Financials
    • 8.2.4 Key Developments
  • 8.3 Chiesi Farmaceutici S.p.A.
    • 8.3.1 Company Overview
    • 8.3.2 Product/Business Segment Overview
    • 8.3.3 Financials
    • 8.3.4 Key Developments
  • 8.4 F. Hoffmann-La Roche AG
    • 8.4.1 Company Overview
    • 8.4.2 Product/Business Segment Overview
    • 8.4.3 Financials
    • 8.4.4 Key Developments
  • 8.5 Gilead Sciences
    • 8.5.1 Company Overview
    • 8.5.2 Product Overview
    • 8.5.3 Financials
    • 8.5.4 Key Developments
  • 8.6 Novartis AG
    • 8.6.1 Company Overview
    • 8.6.2 Product Overview
    • 8.6.3 Financials
    • 8.6.4 Key Developments

  • 8.7 Pharmaxis Ltd.
    • 8.7.1 Company Overview
    • 8.7.2 Product Overview
    • 8.7.3 Financials
    • 8.7.4 Key Developments
  • 8.8 PTC Therapeutics
    • 8.8.1 Company Overview
    • 8.8.2 Product Overview
    • 8.8.3 Financials
    • 8.8.4 Key Developments
  • 8.9 Vertex Pharmaceuticals Incorporated
    • 8.9.1 Company Overview
    • 8.9.2 Product/Business Segment Overview
    • 8.9.3 Financials

List of Tables

List of Tables:

  • TABLE 1 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 2 GLOBAL CYSTIC FIBROSIS MEDICATION MARKET, BY REGION, 2013-2027 ($MILLION)
  • TABLE 3 GLOBAL CYSTIC FIBROSIS DEVICES MARKET, BY REGION, 2013-2027 ($MILLION)
  • TABLE 4 GLOBAL CYSTIC FIBROSIS OTHER TREATMENTS MARKET, BY REGION, 2013-2027 ($MILLION)
  • TABLE 5 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2013-2022 ($MILLION)
  • TABLE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION)
  • TABLE 7 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 8 U.S. CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 9 CANADA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 10 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION)
  • TABLE 11 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 12 GERMANY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 13 FRANCE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 14 U.K. CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 15 ITALY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 16 SPAIN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 17 REST OF WESTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 18 EASTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 19 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION)
  • TABLE 20 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 21 AUSTRALIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 22 JAPAN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 23 CHINA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 24 INDIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 25 REPUBLIC OF KOREA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 26 REST OF ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 27 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2013-2022 ($MILLION)
  • TABLE 28 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 29 MIDDLE EAST CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 30 AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 31 CHIESI FARMACEUTICI S.P.A.: KEY DEVELOPMENTS
  • TABLE 32 VERTEX PHARMACEUTICALS INCORPORATED: KEY DEVELOPMENTS

List of Figures

List of Figures:

  • FIGURE 1 RESEARCH PROCESS OF MRFR
  • FIGURE 2 PORTER'S 5 FORCES ANALYSIS OF GLOBAL CYSTIC FIBROSIS MARKET
  • FIGURE 3 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
  • FIGURE 4 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2015 (%)
  • FIGURE 5 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%)
  • FIGURE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
  • FIGURE 7 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%)
  • FIGURE 8 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
  • FIGURE 9 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%)
  • FIGURE 10 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 % 2022 ($MILLION)
  • FIGURE 11 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2015 (%)
  • FIGURE 12 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
  • FIGURE 13 CYSTIC FINROSIS MARKET SHARE, 2016 (%)
  • FIGURE 14 ABBVIE: RECENT FINANCIAL
  • FIGURE 15 ABBVIE: BUSINESS REVENUE, 2015 (%)
  • FIGURE 16 ABBVIE: GEOGRAPHIC REVENUE, 2015 (%)
  • FIGURE 17 ALLERGAN: RECENT FINANCIAL
  • FIGURE 18 ALLERGAN: BUSINESS REVENUE, 2015 (%)
  • FIGURE 19 ALLERGAN: GEOGRAPHIC REVENUE, 2015 (%)
  • FIGURE 20 CHIESI FARMACEUTICI S.P.A.: RECENT FINANCIALS
  • FIGURE 21 F. HOFFMANN-LA ROCHE AG.: RECENT FINANCIALS
  • FIGURE 22 F. HOFFMANN-LA ROCHE AG.: BUSINESS REVENUE
  • FIGURE 23 GILEAD SCIENCES: RECENT FINANCIAL
  • FIGURE 24 NOVARTIS AG: RECENT FINANCIALS
  • FIGURE 25 NOVARTIS AG: BUSINESS REVENUE, 2015 (%)
  • FIGURE 26 NOVARTIS AG: GEOGRAPHIC REVENUE, 2015 (%)
  • FIGURE 27 PHARMAXIS LTD: RECENT FINANCIALS
  • FIGURE 28 PTC THERAPEUTICS: RECENT FINANCIALS
  • FIGURE 29 PTC THERAPEUTICS: GEOGRAPHICAL REVENUE (%)
  • FIGURE 30 PTC THERAPEUTICS: R&D EXPENSES, 2015 (%)
  • FIGURE 31 VERTEX PHARMACEUTICALS INCORPORATED: RECENT FINANCIALS
  • FIGURE 32 VERTEX PHARMACEUTICALS INCORPORATED: BUSINESS REVENUE
  • FIGURE 33 VERTEX PHARMACEUTICALS INCORPORATED: GEOGRAPHICAL REVENUE
Back to Top